• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: MEDEFIL, INC. NORMAL SALINE IV FLUSH SYRINGE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

MEDEFIL, INC. NORMAL SALINE IV FLUSH SYRINGE Back to Search Results
Catalog Number MIS 1135
Device Problem Insufficient Information (3190)
Patient Problems Fever (1858); Chills (2191)
Event Date 10/24/2014
Event Type  Injury  
Event Description
We received the email concerning this aer from baxter bioscience on 11/03/2014: "an adverse event report was received by the global pharmacovigilance department at the baxter healthcare corporation, in which your product saline flush and heparin flush was listed as a suspect drug.Adverse event(s): fever, chills.(b)(6).No additional information was provided.If you require additional information, please contact the reporter directly.".
 
Manufacturer Narrative
(b)(4).(b)(6).We received this complaint for two of our products (normal saline iv flush syringe and heparin iv flush syringe).According to the initial reporter, during a treatment to the patient, the nurse used advate as an anti-hemophilic treatment from baxter; with our products as concomitants.Therefore, an mdr will be filed for each of these two products.The complainant informed us that the actual samples are not available to return to us for evaluation, but she promised that she will send us some samples from the same lot.Retain samples from the same lot were visually inspected and tested for bacterial endotoxins.Results were negative and no findings were revealed.Further information received from the initial reporter: on (b)(6) 2014, when the patient received advate as an anti-hemophilic treatment from baxter; with our products as concomitants, the patient got the reaction.Reaction occurred within 20 minutes of infusion.Therefore, he was admitted to emergency shortly after reaction and also released from emergency on the same day.The symptoms experienced are not expected for this condition/therapy.Symptoms included fever up to 104 degrees f, shaking chills, hallucinations, and mental status changes.Patient has been on current therapy 1-6 months.The product was infused by a home care rn the investigation is still in progress and will be reported to the fda using a follow-up report.Device not yet received.
 
Manufacturer Narrative
Inadvertently put incorrect "date of this report".The previous report was submitted on 11/12/2014 instead of 11/07/2014.
 
Event Description
We received the email concerning this aer from baxter bioscience on 11/03/2014: "an adverse event report was received by the global pharmacovigilance department at the baxter healthcare corporation, in which your product saline flush and heparin flush was listed as a suspect drug.Adverse event(s): fever, chills.Reporter information: (b)(4).Patient information: pt identifiers: not available dob: (b)(6) 2011.No additional information was provided.If you require additional information, please contact the reporter directly.".
 
Manufacturer Narrative
On monday (b)(6) 2014, we received an update from the initial reporter, ms (b)(6), product coordinator at hemophilia center of western new york, in which she states: ".We have concluded that the adverse reaction was due to the advate.There was no reaction from the saline or heparin flushes provided by your company.Thank you for your involvement with the closure of this event." as a result of this new information and medefil internal complaint investigation, we are closing the complaint and sending this mdr closing report.The additional information confirms that the medefil products were not the causative agent of this adverse event.The complaint will be revisited, if additional information is received from the complainant.
 
Event Description
We received the email concerning this aer from baxter bioscience on (b)(6) 2014: "an adverse event report was received by the global pharmacovigilance department at the baxter healthcare corporation, in which your product saline flush and heparin flush was listed as a suspect drug.Adverse event(s): fever, chills.Reporter information: (b)(6).Patient information: pt identifiers: not available (b)(6).No additional information was provided.If you require additional information, please contact the reporter directly.".
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
NORMAL SALINE IV FLUSH SYRINGE
Type of Device
NORMAL SALINE IV FLUSH SYRINGE
Manufacturer (Section D)
MEDEFIL, INC.
250 windy point drive
glendale heights IL 60139
Manufacturer (Section G)
MEDEFIL, INC.
250 windy point drive
glendale heights IL 60139
Manufacturer Contact
krupal rewanwar
250 windy point drive
glendale heights, IL 60139
6306824600
MDR Report Key4237623
MDR Text Key4997759
Report Number1423982-2014-00002
Device Sequence Number1
Product Code NGT
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
K091583
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Other,Company Representative
Reporter Occupation Other
Remedial Action Other
Type of Report Initial,Followup,Followup
Report Date 11/17/2014
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received11/07/2014
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Nurse
Device Expiration Date07/31/2016
Device Catalogue NumberMIS 1135
Device Lot NumberS14400
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? No
Date Manufacturer Received11/03/2014
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Date Device Manufactured08/05/2014
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Treatment
ADVATE BY BAXTER; HEPARIN IV FLUSH SYRINGE BY MEDEFIL
Patient Outcome(s) Hospitalization;
Patient Age4 YR
-
-